Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.

Also called NCT05032651

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose health services research
Phase
Not applicable
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05032651
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05032651. Randomized; double masking; primary purpose health services research. Start 2021-03-19 (actual); primary completion 2023-12-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients
Acronym
AI
Condition
End Stage Renal Disease on Dialysis
Intervention (Device)
novel artificial intelligence assisted platform
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital (class: other)
Collaborator
National Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct05032651
Content hash
18e3665391db8f8c9f58bab6c97ad7895da273fb968090598a617843d4e6376b